The impact of ACE inhibitors on the risk of SARS-CoV-2 virus infection and the course of COVID-19 disease
DOI:
https://doi.org/10.2478/pjph-2019-0034Keywords:
cardiovascular diseases, angiotensin converting enzyme, SARS-CoV-2 infection, cardiological recommendationsAbstract
Invasion of SARS-CoV-2 virus into human cells is mediated by the interaction of viral particles with a specific protein – angiotensin-converting enzyme 2 (ACE-2). Due to the involvement of ACE-2 in blood pressure regulation, there have appeared reports of possible negative effects of taking some cardiological drugs during coronavirus pandemic. Some hypotheses suggest an increased risk of SARS-CoV-2 infection and more severe clinical course of COVID-19 in patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. In the face of contradictory information regarding this question, several societies of cardiology and hypertension have issued clinical recommendations for patients treated with the above-mentioned drugs. These recommendations conclude that there are no unambiguous data that would support the hypothesis about the negative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on patients infected with SARS-CoV-2 virus. Therefore, it is highly recommended not to discontinue treatment in patients in whom these drugs lead to improvement in their clinical condition. The impact of ACE inhibitors on the risk of SARS-CoV-2 virus infection and the course of COVID-19 disease.
References
1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.
2. Ives CW, Oparil S. What is the first choice for blood pressure treatment? Lancet. 2019;394:1782-4.
3. Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41:12-85.
4. Herman LL, Bashir K. Angiotensin Converting Enzyme Inhibitors (ACEI). In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2019.
5. Chaszczewska-Markowska M, Sagan M, Bogunia-Kubik K. Układ renina angiotensyna aldosteron (RAA) fizjologia i molekularne mechanizmy funkcjonowania. Postepy Hig Med Dośw. 2016;70:917-27
6. Knypl K. Farmakoterapia nadciśnienia tętniczego: inhibitory konwertazy angiotensyny. Med Rodz. 2000:3-4:23-5.
7. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARSCoV-2 by full-length human ACE2. Science. 2020;367:1444-8.
8. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565-74.
9. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605-10.
10. American College of Cardiology. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. ACC News Story. 2020 Mar 17. https://viajwat.ch/2REZU2H. (dostęp:10.05.2020 r.)
11. Statement of the European Society of Hypertension (ESH) on hypertension, Renin-Angiotensin System (RAS) blockers and COVID-19. https://www.eshonline.org/spotlights/esh-statement-covid-19/ (dostęp: 10.05.2020)
12. https://pulsmedycyny.pl/leki-hipotensyjne-a-zachorowania-na-covid-19-jakie-sa-wytyczne-towarzystw-naukowych-986648 (dostęp: 10.05.2020)
13. https://nadcisnienietetnicze.pl/informacja-dla-pacjentow-stosujacych-terapie-hipotensyjna-w-kontekscie-pandemii-sars-cov-2 (dostęp: 10.05.2020)
14. Mehra MR, Desai SS, Kuy S, et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020;NEJMoa2007621.
15. Coronavirus (COVID-19) ACEi/ARB Investigation (CORONACION), https://clinicaltrials.gov/ct2/show/NCT04330300 (dostęp: 15.05.2020)
16. Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID), https://clinicaltrials.gov/ct2/show/NCT04355429 (dostęp: 15.05.2020).
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Polish Journal of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
